Comparative Pharmacology
Head-to-head clinical analysis: DDAVP versus DESMODA.
Peer-Reviewed Evidence
Head-to-head clinical analysis: DDAVP versus DESMODA.
DDAVP vs DESMODA
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Synthetic analog of vasopressin; primarily activates V2 receptors in renal collecting ducts, increasing water reabsorption and concentrating urine.
Desmopressin is a synthetic analogue of vasopressin (antidiuretic hormone, ADH) that acts on V2 receptors in renal collecting ducts, increasing water reabsorption and reducing urine output. It also raises plasma levels of factor VIII and von Willebrand factor via V2 receptor stimulation on endothelial cells.
Central diabetes insipidus: 0.1-0.4 mg orally every 12-24 hours or 0.5-1 mcg subcutaneously/intranasally every 12-24 hours. Nocturnal enuresis: 0.2-0.4 mg orally at bedtime. Hemophilia A/von Willebrand disease: 0.3 mcg/kg intravenous over 15-30 minutes or 300 mcg subcutaneously or 150 mcg intranasally (for >50 kg).
10 mg orally once daily
None Documented
None Documented
Terminal elimination half-life: 2-3 hours (intravenous); 3.4-4.4 hours (oral); clinical context: antidiuretic effect persists longer (6-20 hours) due to receptor binding.
Terminal half-life: 8-12 hours; extended in renal impairment (up to 24 hours).
Primarily renal (unchanged drug); >90% eliminated by kidneys.
Renal: ~70% unchanged; biliary/fecal: ~30% as metabolites.
Category C
Category C
Antidiuretic Hormone Analog
Antidiuretic Hormone Analog